Cell Growth & Differentiation, Vol 7, Issue 1 65-74, Copyright © 1996 by American Association of Cancer Research

ARTICLES

Differential effects of retinoids and antiestrogens on cell cycle progression and cell cycle regulatory genes in human breast cancer cells

NR Wilcken, B Sarcevic, EA Musgrove and RL Sutherland
Garvan Institute of Medical Research, St. Vincent's Hospital, Darlinghurst, NSW, Australia.

Retinoids have antiproliferative effects in human breast cancer cells and share some characteristics with antiestrogens, although the molecular targets involved have yet to be identified in either case. Using T-47D human breast cancer cells, we compared the effects of retinoic acid (RA) and the antiestrogen ICI 164384 on cell cycle phase distribution and the expression of genes with known functions in cell cycle control. Both RA and ICI 164384 inhibited cell cycle progression in G1 phase, but the RA effect was delayed by 16 h. This delay in action was also seen with 9-cis RA and other retinoids. Administration of 17 beta-estradiol abolished the effects of ICI 164384 but was without effect in RA-treated cells. Antiestrogen treatment caused a rapid inhibition of c-myc and cyclin D1 gene expression and reduced Cdk2 activity by more than 50% at 24 h. RA, however, did not affect c-myc or cyclin D1 gene expression, nor did it significantly change the mRNA or protein levels of cyclins D3 or E or cyclin-dependent kinases (CDK) Cdk2 or Cdk4. RA-induced reduction in Cdk2 activity was modest and occurred after %S phase declined, while Cdk4 activity was reduced, coincident with cell cycle changes. However, following either RA or ICI 164384, there was a reduction in the amount of hyperphosphorylated pRB, first apparent well before cell cycle changes were seen. These data demonstrate that: (a) the mechanisms of action of antiestrogens and retinoids are different but converge at pRB; and (b) RA can affect CDK activity without reducing cyclin or CDK levels.

This article has been cited by other articles:

				D N Danforth Jr All trans-retinoic acid acts synergistically with hydroxytamoxifen and transforming-growth factor {beta} to stimulate apoptosis in MCF-7 breast cancer cells J. Endocrinol., November 1, 2004; 183(2): 395 - 404. [Abstract] [Full Text] [PDF]

				K. J. Soprano and D. R. Soprano Retinoic Acid Receptors and Cancer J. Nutr., December 1, 2002; 132(12): 3809S - 3813. [Abstract] [Full Text] [PDF]

				J. S. Carroll, A. Swarbrick, E. A. Musgrove, and R. L. Sutherland Mechanisms of Growth Arrest by c-myc Antisense Oligonucleotides in MCF-7 Breast Cancer Cells: Implications for the Antiproliferative Effects of Antiestrogens Cancer Res., June 1, 2002; 62(11): 3126 - 3131. [Abstract] [Full Text] [PDF]

				E. C. Tibaduiza, J. C. Fleet, R. M. Russell, and N. I. Krinsky Excentric Cleavage Products of {beta}-Carotene Inhibit Estrogen Receptor Positive and Negative Breast Tumor Cell Growth In Vitro and Inhibit Activator Protein-1-Mediated Transcriptional Activation J. Nutr., June 1, 2002; 132(6): 1368 - 1375. [Abstract] [Full Text] [PDF]

				D. Rivenzon-Segal, E. Rushkin, S. Polak-Charcon, and H. Degani Glucose transporters and transport kinetics in retinoic acid-differentiated T47D human breast cancer cells Am J Physiol Endocrinol Metab, September 1, 2000; 279(3): E508 - E519. [Abstract] [Full Text] [PDF]

				E. Nabeyrat, S. Corroyer, R. Epaud, V. Besnard, V. Cazals, and A. Clement Retinoic acid-induced proliferation of lung alveolar epithelial cells is linked to p21CIP1 downregulation Am J Physiol Lung Cell Mol Physiol, January 1, 2000; 278(1): L42 - L50. [Abstract] [Full Text] [PDF]

				W. Wang, L. Dong, B. Saville, and S. Safe Transcriptional Activation of E2F1 Gene Expression by 17{beta}-Estradiol in MCF-7 Cells Is Regulated by NF-Y-Sp1/Estrogen Receptor Interactions Mol. Endocrinol., August 1, 1999; 13(8): 1373 - 1387. [Abstract] [Full Text]

				V. L. Seewaldt, E. C. Dietze, B. S. Johnson, S. J. Collins, and M. B. Parker Retinoic Acid-mediated G1-S-Phase Arrest of Normal Human Mammary Epithelial Cells Is Independent of the Level of p53 Protein Expression Cell Growth Differ., January 1, 1999; 10(1): 49 - 59. [Abstract] [Full Text]

				J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]

				C. M. Cover, S. J. Hsieh, S. H. Tran, G. Hallden, G. S. Kim, L. F. Bjeldanes, and G. L. Firestone Indole-3-carbinol Inhibits the Expression of Cyclin-dependent Kinase-6 and Induces a G1 Cell Cycle Arrest of Human Breast Cancer Cells Independent of Estrogen Receptor Signaling J. Biol. Chem., February 13, 1998; 273(7): 3838 - 3847. [Abstract] [Full Text] [PDF]

				C. Teixeira and M. A. C. Pratt CDK2 Is a Target for Retinoic Acid-Mediated Growth Inhibition in MCF-7 Human Breast Cancer Cells Mol. Endocrinol., August 1, 1997; 11(9): 1191 - 1202. [Abstract] [Full Text]

				E. A. Musgrove, C. S. L. Lee, A. L. Cornish, A. Swarbrick, and R. L. Sutherland Antiprogestin Inhibition of Cell Cycle Progression in T-47D Breast Cancer Cells Is Accompanied by Induction of the Cyclin-Dependent Kinase Inhibitor p21 Mol. Endocrinol., January 1, 1997; 11(1): 54 - 66. [Abstract] [Full Text]